Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Insilico Medicine IPO: Shortening Drug Discovery Period Through AI-Driven Platform Holds Promise

InSilico Medicine (ISM HK): Firing on Both Cylinders

InSilico Medicine (英矽智能) IPO: AI Assets as Upside

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/insilico-medicine-cayman-topco" target="_blank" data-smartkarma-citation="entities:39890:1" rel="noopener">InSilico Medicine Cayman TopCo (ISM HK)</a> has announced 2025 results. 8x jump in revenue generated from drug discovery and 24% YoY growth in software revenue are two positive takeaways.</li>
<li>In 2025, newly signed agreements totaled $1.3B, bringing cumulative collaboration value to $4.6B. Thus far, $205M revenue has been realized, with $4.4B potential revenue expected to be realized in future.</li>
<li>InSilico reached drug discovery collaboration with Eli Lilly for $115M upfront payment. Total deal value (upfront+ milestone) is $2.75B, plus tiered royalties on future sales.</li>
</ul>



InSilico Medicine Cayman TopCo (ISM HK) has announced 2025 results. 8x jump in revenue generated from drug discovery and 24% YoY growth in software revenue are two positive takeaways.
In 2025, newly signed agreements totaled $1.3B, bringing cumulative collaboration value to $4.6B. Thus far, $205M revenue has been realized, with $4.4B potential revenue expected to be realized in future.
InSilico reached drug discovery collaboration with Eli Lilly for $115M upfront payment. Total deal value (upfront+ milestone) is $2.75B, plus tiered royalties on future sales.


인실리코 메디신(ISM HK): AI 기반 신약 개발로 2025년 실적 호조 예상; 릴리와 새로운 계약 체결